Technology
Technology
VaxSyna's Vaccine Platform Offers:
Full Protection in 1-2 Doses
No Adjuvant Required
Multiple Antigen Display
Easy to Tailor
Thermally Stable
Synergy with VLPs
Agnostic of Antigen size
Prophylactic & Therapeutic
VaxSyna's Vaccine Platform is a Proprietary Recombinant Antibody- Antigen Conjugate
VaxSyna is developing a patented vaccine platform called a Recombinant Immune Complex (RIC). RICs contain an antibody fused to a vaccine antigen that is tagged with epitope specific to the antibody. The antigen can be displayed on either the N- or C-terminus of the human IgG prior to expression. The antibody binds to the epitope tag forming highly immunogenic complexes that trigger the immune system through Fc-gamma receptors and crosslinking of B cell receptors.
VaxSyna's Vaccine Platform can be utilized to create both prophylactic and therapeutic vaccines.
VaxSyna's Manufacturing Platform
High Yield
Quick Expression
Low COGs
Safe
VaxSyna's Plant Manufacturing uses Proprietary Optimization
VaxSyna uses an optimized vaccine antigen expression platform in Nicotiana benthamiana to keep R&D costs down, with multiple other benefits. Plant expression systems have shown:
50% reduced manufacturing costs
Safe, no human or pathogen contamination
Harbor human-like glycosylation patterns
Linear scale up-- VaxSyna’s system particularly have high yield with 3mg protein per gram leaf mass
Quick expression 4-5 days
Relevant Publications
Diamos AG, Pardhe MD, Bergeman MH, Kamzina AS, DiPalma MP, Aman S, et al. A self-binding immune complex vaccine elicits strong neutralizing responses against herpes simplex virus in mice. Front Immunol 2023;14:1085911. https://doi.org/10.3389/fimmu.2023.1085911.
Kamzina AS, DiPalma MP, Hunter JGL, Diamos AG, Armer B, Mor TS, et al. Production of IgG Fusion Proteins Transiently Expressed in Nicotiana benthamiana. J Vis Exp 2021. https://doi.org/10.3791/61774.
Diamos AG, Pardhe MD, Sun H, Hunter JGL, Mor T, Meador L, et al. Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity. Vaccine 2020;38:3455–63. https://doi.org/10.1016/j.vaccine.2020.02.089.
Diamos AG, Pardhe MD, Sun H, Hunter JGL, Kilbourne J, Chen Q, et al. A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant. Front Immunol 2020;11:576012. https://doi.org/10.3389/fimmu.2020.576012.
Diamos AG, Hunter JGL, Pardhe MD, Rosenthal SH, Sun H, Foster BC, et al. High Level Production of Monoclonal Antibodies Using an Optimized Plant Expression System. Frontiers Bioeng Biotechnology 2020;7:472. https://doi.org/10.3389/fbioe.2019.00472.
Diamos AG, Larios D, Brown L, Kilbourne J, Kim HS, Saxena D, et al. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen. Vaccine 2019;37:137–44. https://doi.org/10.1016/j.vaccine.2018.11.021.
Diamos AG, Mason HS. High-level expression and enrichment of norovirus virus-like particles in plants using modified geminiviral vectors. Protein Expres Purif 2018;151:86–92. https://doi.org/10.1016/j.pep.2018.06.011.
Mason HS. Recombinant immune complexes as versatile and potent vaccines. Hum Vacc Immunother 2016;12:988–9. https://doi.org/10.1080/21645515.2015.1116655.